More News! Selexis’ acquisition & a potential cure for rare liver disease

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • Selexis was acquired by JSR Life Sciences, though terms were not disclosed
  • Sanofi could pour up to €2B into biologics production in the next 3 years
  • Numab struck a licensing deal with Japanese pharma Kaken, for which no financial details were disclosed
  • Kiadis banked €5M in a private placement
  • Cantargia signed a deal with Panorama Research Inc to develop and antibody against IL1RAP for autoimmune and inflammatory diseases
Oleksii G
  • The Medical University of Vienna reports initial success treating a liver disorder that is so far incurable
  • RedHill announced positive Phase III results for its small molecule, BEKINDA, in gastroenteritis
  • Patients with aggressive prostate cancer were identified thanks to a red blood cell technique developed by researchers at the Queen Mary University of London

Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.